Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.verified

DUL.DE

Price:

$393.8

Market Cap:

$60.52B

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1)...[Read more]

Industry

Biotechnology

IPO Date

2007-12-11

Stock Exchange

XETRA

Ticker

DUL.DE

The Enterprise Value as of December 2025 (TTM) for Alnylam Pharmaceuticals, Inc. (DUL.DE) is 61.81B

According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 61.81B. This represents a change of 42.18% compared to the average of 43.47B of the last 4 quarters.

Alnylam Pharmaceuticals, Inc. (DUL.DE) Historical Enterprise Value (quarterly & annually)

How has DUL.DE Enterprise Value performed in the past?

The mean historical Enterprise Value of Alnylam Pharmaceuticals, Inc. over the last ten years is 16.04B. The current 61.81B Enterprise Value has changed 38.42% with respect to the historical average. Over the past ten years (40 quarters), DUL.DE's Enterprise Value was at its highest in in the September 2025 quarter at 61.22B. The Enterprise Value was at its lowest in in the December 2016 quarter at 3.17B.

Quarterly (TTM)
Annual

Average

16.04B

Median

13.65B

Minimum

3.16B

Maximum

30.37B

Alnylam Pharmaceuticals, Inc. (DUL.DE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 244.49%

Maximum Annual Enterprise Value = 30.37B

Minimum Annual Increase = -59.09%

Minimum Annual Enterprise Value = 3.16B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202430.37B24.45%
202324.40B-16.93%
202229.37B44.95%
202120.26B35.37%
202014.97B21.30%
201912.34B77.72%
20186.94B-36.23%
201710.89B244.49%
20163.16B-59.09%
20157.73B8.36%

Alnylam Pharmaceuticals, Inc. (DUL.DE) Average Enterprise Value

How has DUL.DE Enterprise Value performed in the past?

The current Enterprise Value of Alnylam Pharmaceuticals, Inc. (DUL.DE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

28.05B

5-year avg

23.88B

10-year avg

16.04B

Alnylam Pharmaceuticals, Inc. (DUL.DE) Enterprise Value vs. Peers

How is DUL.DE’s Enterprise Value compared to its peers?

Alnylam Pharmaceuticals, Inc.’s Enterprise Value is greater than Siemens Healthineers AG (61.69B), greater than Merck KGaA (60.79B), greater than Zoetis Inc. (50.41B), greater than BioNTech SE (9.72B), greater than Veeva Systems Inc. (38.21B), less than Vertex Pharmaceuticals Incorporated (113.78B), greater than Moderna, Inc. (10.38B), less than Cigna Corporation (98.92B), less than Bayer AG (66.68B), greater than Verastem, Inc. (547.57M),

Build a custom stock screener for Alnylam Pharmaceuticals, Inc. (DUL.DE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alnylam Pharmaceuticals, Inc. (DUL.DE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Alnylam Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Alnylam Pharmaceuticals, Inc. (DUL.DE)?

What is the 3-year average Enterprise Value for Alnylam Pharmaceuticals, Inc. (DUL.DE)?

What is the 5-year average Enterprise Value for Alnylam Pharmaceuticals, Inc. (DUL.DE)?

How does the current Enterprise Value for Alnylam Pharmaceuticals, Inc. (DUL.DE) compare to its historical average?